Anti-obesity pharmacotherapy: Future perspectives utilising 5-HT2C receptor agonists

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 4, 2006, Pages 577-583

  Dutton, Alice C ^a   Barnes, Nicholas M ^a  

^a Department of Pharmacology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 PYRROLO(ISO)QUINOLINYL] 2 PROPYLAMINE; 1,4 DIHYDROINDENO[1,2 B]PYRROLE DERIVATIVE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 5384; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ANTIOBESITY AGENT; APD 356; ATHX 105; ATHX 88651; BVT 933; FENFLURAMINE; IL 639; INDOLE DERIVATIVE; LORCASERIN; LY 448100; PIPERAZINE DERIVATIVE; PLACEBO; PYRAZINE DERIVATIVE; RO 600032; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VER 2692; VER 3323; VER 5384; VER 5593; WAY 161503; WAY 163909; WAY 629; YM 348;

BINDING AFFINITY; BODY MASS; CARDIOVASCULAR DISEASE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIDEMIC; FEEDING BEHAVIOR; FOOD INTAKE; HEADACHE; HUMAN; NAUSEA; NEUROTRANSMISSION; NONHUMAN; OBESITY; PULMONARY HYPERTENSION; REVIEW; SEROTONINERGIC SYSTEM; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE;

EID: 33846262179     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.11.005     Document Type: Review

References (51)

1. Halford J.C. Obesity drugs in clinical development. Curr. Opin. Invest. Drugs 7 (2006) 312-318
2. Blundell J.E. Serotonin manipulations and the structure of feeding behaviour. Appetite 7 (1988) 39-56
3. Goodall E., and Silverstone T. The interaction of metergoline, a 5-HT receptor blocker, and dexfenfluramine in human feeding. Clin. Neuropharmacol. 11 (1988) S135-S138
4. Rowland N.E., and Carlton J. Neurobiology of an anorectic drug: fenfluramine. Progr. Neurobiol. 27 (1986) 13-62
5. Clifton P.G., et al. A behavioural profile of fluoxetine-induced anorexia. Psychopharmacology 97 (1989) 89-95
6. McGuirk J., and Silverstone T. The effect of the 5-HT reuptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. Int. J. Obesity 14 (1990) 361-372
7. Saller C.F., and Stricker E.M. Hyperphagia and increased growth in rats after intraventricular injection of 5,7-dihydroxytryptamine. Science 192 (1976) 385-387
8. Lee M.D., et al. Tonic regulation of satiety by 5-HT1B receptors in the mouse: converging evidence from behavioural and c-fos immunoreactivity studies. Eur. J. Neurosci. 19 (2004) 3017-3025
9. Lucas J.J., et al. Absence of fenfluramine-induced anorexia and reduced c-Fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice. J. Neurosci. 18 (1998) 5537-5544
10. Bouwknecht J.A., et al. Male and female 5-HT(1B) receptor knockout mice have higher body weights than wildtypes. Physiol. Behav. 74 (2001) 507-516
11. Kennett G.A., et al. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36 (1997) 609-620
12. Schreiber R., and De Vry J. Role of 5-HT2C receptors in the hypophagic effect of m-CPP, ORG 37684 and CP-94,253 in the rat. Progr. Neuro-Psychopharmacol. Biol. Psychiatry 26 (2002) 441-449
13. Clifton P.G., et al. Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist, and d-fenfluramine on feeding patterns in the rat. Psychopharmacology 152 (2000) 256-267
14. Curzon G., et al. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol. Sci. 18 (1997) 21-25
15. Knight A.R., et al. Pharmacological characterisation of the agonist radioligand binding site of 5-HT2A, 5-HT2B and 5-HT2C receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 370 (2004) 114-123
16. Vickers S.P., et al. Evidence that hypophagia indiced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 41 (2001) 200-209
17. Grignaschi G., and Samanin R. Role of serotonin receptors in the effect of d-fenfluramine on feeding patterns in the rat. Eur. J. Pharmacol. 212 (1992) 287-289
18. Dalton G.L., et al. Serotonin 1B and 2C receptor interactions in the modulation of feeding behaviour in the mouse. Psychopharmacology 185 (2006) 45-57
19. Tecott L.H., and Abdallah L. Mouse genetic approaches to feeding regulation: serotonin 5-HT2C receptor mutant mice. CNS Spectrums 8 (2003) 584-588
20. Tecott L.H., et al. Eating disorder and epilepsy in mice lacking 5HT2C serotonin receptors. Nature 374 (1995) 542-546
21. Nonogaki K., et al. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat. Med. 4 (1998) 1152-1156
22. Nonogaki K., et al. Hyperactivity and reduced energy cost of physical activity in serotonin 5-HT2C receptor mutant mice. Diabetes 52 (2003) 315-320
23. Ellingrod V.L., et al. Weight gain associated with the -759 C/T polymorphism of the 5HT2C receptor and olanzapine. Am. J. Med. Genet. Part B 134B (2005) 76-78
24. Miller D.D., et al. Cllozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am. J. Med. Genet. Part B 133B (2005) 97-100
25. Buckland P.R., et al. Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain. Am. J. Psychiatry 162 (2005) 613-615
26. 2C receptor (HTR2C) and other genes. Pharmacogenet. Genomics 15 (2005) 193-194
27. Smith B.M., et al. The potential use of selective 5-HT2C agonists in treating obesity. Expert Opin. Invest. Drugs 14 (2006) 257-266
28. Rothman R.B., et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102 (2000) 2836-2841
29. Smith B.M., et al. Discovery and SAR of new benzazepines as potent and selective 5-HT2C receptor agonists for the treatment of obesity. Bioorg. Med. Chem. Lett. 15 (2005) 1467-1470
30. Svartengren J., et al. Preclinical in vivo pharmacology of BVT.933, a selective 5-HT2C receptor agonist. Soc. Neurosci. (2003) (Abstracts 29, 509.9)
31. Nilsson B.M. 5-Hydroxytryptamine2C (5-HT2C) receptor agonists as potential antiobesity agents. J. Med. Chem. 49 (2006) 4023-4034
32. Bentley J.M., et al. Indoline derivatives as 5-HT2C receptor agonists. Bioorg. Med. Chem. Lett. 14 (2004) 2367-2370
33. Adams D.R., et al. Pyrrolo(iso)quinoline derivatives as 5-HT2C receptor agonists. Bioorg. Med. Chem. Lett. 16 (2006) 677-680
34. Richter H.G.F., et al. Synthesis and biological evaluation of novel hexahydro-pyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT2C receptor agonists. Bioorg. Med. Chem. Lett. 16 (2006) 1207-1211
35. Welmaker G.S., et al. Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-Hexahydro-1H-pyrazino[1,2-a]quinoxalines. Bioorg. Med. Chem. Lett. 10 (2000) 1991-1994
36. Sabb A.L., et al. Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor. Bioorg. Med. Chem. Lett. 14 (2004) 2603-2607
37. Dunlop J., et al. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bhcyclopenta-[b][1,4]diazepino [6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor selective agonist with anorectic activity. J. Pharmacol. Exp. Ther. 313 (2005) 862-869
38. Rosenzweig-Lipson S., et al. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503. Brain Res. 1073-1074 (2006) 240-251
39. Hayashi A., et al. Antiobesity effect of YM348, a novel 5-HT2C receptor agonist in Zucker rats. Brain Res. 1011 (2004) 221-227
40. Kimura Y., et al. Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist. Eur. J. Pharmacol. 483 (2004) 37-43
41. Isaac M., et al. Pyrrolo[3,2,1-ij]quinoline derivatives, a 5-HT2c receptor agonist with selectivity over the 5-HT2a receptor: potential therapeutic applications for epilepsy and obesity. Bioorg. Med. Chem. Lett. 10 (2000) 919-921
42. Briner, K. et al. (2001) Novel benzothiophenes and their use as 5-HT2C receptor agonists. WO-00109126
43. Robichaud, A.J. et al. (2002) Substituted pyridoindoles as serotonin agonists and antagonists. WO-02059129
44. Martin J.R., et al. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J. Pharmacol. Exp. Ther. 286 (1998) 913-924
45. Ladoucer, G.H. et al. (2003) Novel 1-(2-aminoalkyl)-1H-pyrazole derivatives useful as 5-HT2C ligands for the treatment of obesity and eating disorders. WO-03057674
46. Chian, P.Y.C. et al. (2003) Piperazine derivative 5-HT receptor ligands. WO-03000663
47. 2C receptor. Neuropsychopharmacology 27 (2002) 869-873
48. 2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 60 (2005) 441-460
49. 2C receptor-mediated weight control in rats. Psychpharmacology 178 (2005) 241-249
50. 2C receptor alters agonist-receptor-effector coupling specificity. Br. J. Pharmacol. 134 (2001) 386-392
51. Roth B.L., et al. The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches?. Neuroscientist 6 (2000) 252-262